Key Highlights
• Shares traded at $16.70 pre-market, down 11.87% from the $18.95 prior close.
• Third-quarter Revenue of $91.3 million rose 34% year over year.
• Full-year revenue guidance was raised to $344 million to $346 million.
• Wei-Li Shao becomes CEO on January 1, 2027, succeeding Sean Duffy.
Omada Health (NASDAQ:OMDA) shares were lower in pre-market trading on Friday, November 6, at $16.70, down 11.87%, after the company reported third-quarter 2026 results above estimates and raised its full-year outlook. Revenue rose 34% to $91.3 million, against an estimate of $85.6 million, and adjusted EPS was $0.10, against $0.09. The sector ETF was down roughly 1% pre-market, a smaller move than Omada's, as the Nasdaq remained under pressure after Thursday's AI-led selloff.
The South San Francisco-based company delivers human-led coaching, connected devices and AI-enabled support for cardiometabolic and related chronic conditions, selling mainly to employers, health plans, health systems and pharmacy benefit managers.
Members, Retention and Revenue per Member
Total members reached about 1.134 million, up 36% year over year, with about 43,000 net adds. Retention improved to 58% from 43% in the fourth quarter of 2024, and average tenure is about two years and four months. Investors are weighing a member count that came in slightly below analyst estimates.
Trailing 12-month non-GAAP cost of revenue per member fell to a record low of $81, while revenue per member rose to $294. Growth was driven by diabetes and hypertension enrollments, July and August enrollments, and a mix shift toward higher-priced programs.
Profitability, Cash and the Raised Full-Year Range
GAAP gross Margin was 76% and non-GAAP gross margin was 78%, up from 66% and 68% a year earlier. GAAP Net Income was $6.6 million, and adjusted EBITDA reached a record $12 million, about a 14% margin. Cash was about $243 million, with no debt.
Full-year 2026 revenue guidance was raised to $344 million to $346 million, from $334 million to $340 million, about 33% growth at the midpoint. Adjusted EBITDA guidance was raised to $32 million to $34 million, from $21 million to $27 million.
Fourth-Quarter Step-Down and the GLP-1 Selling Season
For the fourth quarter, the company expects revenue below the third quarter, with new enrollments declining sequentially on seasonality and total members stepping down slightly. Adjusted EBITDA is expected to moderate as R&D headcount is added and care team staffing ramps for the 2027 benefit launch. Management reiterated an 80% long-term gross margin target and a 20% or higher growth target.
Management said GLP-1 coverage uncertainty and rising costs are extending the selling season deeper into the fourth quarter, so it declined to quantify 2027 covered lives. The HCSC expansion adds an estimated 1.5 million covered lives across three states, launching January 1, 2027. Management cited 40% to 50% of new deals as multi-condition, and a GLP-1 FlexCare offering for employers that do not cover GLP-1s.
January 1 Brings the HCSC Launch and the CEO Handoff
Two dates frame the next stretch. The HCSC expansion launches on January 1, 2027, the same day Wei-Li Shao becomes CEO and co-founder Sean Duffy becomes Executive Chair. Fourth-quarter results will show how enrollment seasonality and staffing costs compare with the raised full-year range.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...